Antiobesity effect of YM348, a novel 5-HT2C receptor agonist, in Zucker rats

@article{Hayashi2004AntiobesityEO,
  title={Antiobesity effect of YM348, a novel 5-HT2C receptor agonist, in Zucker rats},
  author={Aska Hayashi and Rie Sonoda and Yasuharu Kimura and Toshiyuki Takasu and Masanori Suzuki and Masao Sasamata and Keiji Miyata},
  journal={Brain Research},
  year={2004},
  volume={1011},
  pages={221-227}
}
The purpose of the present study was to investigate the potency of (S)-2-(7-ethyl-1H-furo[2,3-g]indazol-1-yl)-1-methylethylamine (YM348), a 5-HT2C receptor agonist, as an antiobesity agent in Zucker rats. Single oral administration of YM348 at 0.1, 0.3, 1 and 3 mg/kg significantly reduced food intake in a dose-dependent manner. This effect of YM348 on food intake was inhibited by SB242084, a selective 5-HT2C receptor antagonist. In addition, single administration of YM348 significantly… 
Agonist diversity in 5-HT2C receptor-mediated weight control in rats
TLDR
Together, the difference between compounds in their hypophagic effects and the similarity in their hyperthermic effects suggest a diversity in agonists in 5-HT2C receptor-mediated weight control in rats.
Serotonin 1B and 2C receptor interactions in the modulation of feeding behaviour in the mouse
TLDR
5-HT2C-R and 5-HT1B-R activation are each sufficient to induce a hypophagic response, however, concurrent 5- HT2c-R inactivation can potentiate the hypophotic response to 5-ht1b-Ractivation, consistent with an inhibitory role for the 5-hydroxytryptamine-based response in behaviour mediated by the activation of other 4-HT receptors.
Antiobesity-like effects of the 5-HT2C receptor agonist WAY-161503
TLDR
In vivo and chronic administration of WAY-161503 to obese Zuker rats, the rats maintained a 30% decrease in food intake over the 15-day period combined with a 25 g decrease in body weight relative to vehicle-treated controls demonstrating a lack of tolerance to its anorectic effects.
Lorcaserin, a Novel Selective Human 5-Hydroxytryptamine2C Agonist: in Vitro and in Vivo Pharmacological Characterization
TLDR
Data demonstrate lorcaserin to be a potent, selective, and efficacious agonist of the 5-HT2C receptor, with potential for the treatment of obesity.
Antidepressant-like effects of the novel, selective, 5-HT2C receptor agonist WAY-163909 in rodents
TLDR
The results demonstrate that the novel 5-HT2C receptor agonist WAY-163909 produces rapid onset antidepressant-like effects in animal models and may be a novel treatment for depression.
Pharmacological profile of the 5-HT(2C) receptor agonist WAY-163909; therapeutic potential in multiple indications.
TLDR
5-HT(2C) receptor selective agonist WAY-163909 was found to have robust dose-dependent effects in animal models of obesity, psychotic-like behavior or depression, consistent with a potential therapeutic utility in obesity, schizophrenia and depression.
5-HT(2C) receptor agonists and the control of appetite.
TLDR
Lorcaserin, a selective 5-HT(2C) receptor agonist, is a novel anti-obesity agent that reduces both energy intake and body weight and remains to be characterised as does its behavioural specificity.
Systemic administration of 5-HT2C receptor agonists attenuates muscular hyperalgesia in reserpine-induced myalgia model
TLDR
It is suggested that 5-HT(2C) receptor agonists have therapeutic potential for treating chronic pain in patients with fibromyalgia although clinical extrapolation remains to be a future challenge.
Atypical antipsychotics and effects of adrenergic and serotonergic receptor binding on insulin secretion in-vivo: An animal model
TLDR
Results suggest that α1 and 5HT2A receptor antagonism may be involved in glucose dysregulation with AAP treatment, however, the exact mechanisms involved remain unknown.
Serotonin 5-ht2c receptor agonists: potential for the treatment of obesity.
  • K. Miller
  • Medicine
    Molecular interventions
  • 2005
TLDR
Development of highly selective 5-HT(2C) agonists may recapitulate the clinical anti-obesity properties observed with fenfluramine while avoiding the significant cardiovascular and pulmonary side effects.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 27 REFERENCES
Pharmacological profile of YM348, a novel, potent and orally active 5-HT2C receptor agonist.
TLDR
In conclusion, YM348 is a novel, potent and orally active 5-HT(2C) receptor agonist, and neither the activation of 4-fluoronaphth-1-yl)-6-isopropylpyrimidine nor a cardiovascular effect is likely to contribute to the inverted U-shape dose-response curve for penile erections.
Similarities in the action of Ro 60-0175, a 5-HT2C receptor agonist, and d-fenfluramine on feeding patterns in the rat
TLDR
The hypothesis that activation of 5-HT2C receptors is a critical aspect of the hypophagic action of d-fenfluramine is supported and may prove to be a useful target in the development of clinically effective drugs for the treatment of obesity.
Effects of RO 60 0175, a 5-HT(2C) receptor agonist, in three animal models of anxiety.
TLDR
The effects of the novel 5-HT(2C) receptor agonist, RO 60 0175, in three models of anxiety were tested, and it was found to induce hypolocomotion in rats at doses greater than 0.5 mg/kg s.c, but was neither anxiolytic, nor clearly anxiogenic at the doses tested.
Chronic treatment with meta-chlorophenylpiperazine (m-CPP) alters behavioral and cerebral metabolic responses to the serotonin agonists m-CPP and quipazine but not 8-hydroxy-2(di-N-propylamino)tetralin
TLDR
It is suggested that hypolocomotion and the serotonin syndrome are mediated by different 5-HT receptor subtypes, and that chronic m-CPP administration produces functional down-regulation of 5- HT1B/1C but not of 5 -HT1A-coupled mechanisms.
Evidence thatm-chlorophenylpiperazine-induced hyperthermia in rats is mediated by stimulation of 5-HT2C receptors
TLDR
Findings suggest thatm-CPP-induced hyperthermia in rats is mediated by selective stimulation of 5-HT2C receptors.
Evidence that hypophagia induced bymCPP and TFMPP requires 5-HT1C and 5-HT1B receptors; hypophagia induced by RU 24969 only requires 5-HT1B receptors
TLDR
The results suggest that RU 24969-induced hypophagia depends on 5-HT1B receptors but not on 5,HT1C receptors, whilemCPP (and TFMPP)-induced hypolocomotion may depend on both receptors.
The effect of 8-OH-DPAT on temperature in the rat and its modification by chronic antidepressant treatments
TLDR
It is concluded that rat rectal temperature can be a useful model to help assess the functional state of serotonergic mechanisms, including the adaptational changes induced by long-term antidepressant treatment.
Activation of hypothalamic serotonin receptors reduced intake of dietary fat and protein but not carbohydrate.
TLDR
Results demonstrate a selective effect of exogenous serotonergic drugs in the hypothalamus to reduce fat rather than carbohydrate intake and suggest that higher baseline fat intake enhances responsivity to serotonergy drugs.
Evidence that mCPP may have behavioural effects mediated by central 5‐HT1C receptors
TLDR
As mianserin, cyproheptadine and mesulergine in the absence of mCPP did not increase locomotion but increased the number of feeding scores, the activation of 5‐HT1C‐receptors may be of physiological importance in the control of appetite.
Hyperthermia induced by m-CPP in the rat and its modification by antidepressant treatments
TLDR
In studies investigating the modification of the response by antidepressant treatments both acute (3 day) and chronic (22 day) administration of the MAO inhibitor clorgyline, as well as the tricyclics clomipramine and imipramines, attenuated the hyperthermic response to m-CPP.
...
1
2
3
...